Intrinsiqq
Lite Strategy, Inc. logo

Lite Strategy, Inc. Insider Trading

LITS

⊜ Compare
Last 12 months

Insiders bought 142K on the open market and sold nothing.

Net open-market
+142K
3 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
1 / 0
executives and directors
Last open-market buy
Jun 2026
Jun 24, 2026

Get an email when LITS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jun 24
    James P Flynn
    Director · bought 25,000 at $0.86
    22K
    25% of stake
  • Dec 19, 2025
    James P Flynn
    Director · bought 70,000 at $1.40
    98K
    233% of stake
  • Dec 18, 2025No plan
    Alexander Schornstein
    Large holder · sold 690,611 at $1.37
    946K
    16% of stake
  • Nov 19, 2025
    James P Flynn
    Director · bought 12,100 at $1.88
    23K
    68% of stake
  • Jul 22, 2025 – Jul 23, 2025
    Nicholas Glover
    Director · bought 2,000 at avg $6.28
    13K
    New position
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LITS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with LITS

CompareIntrinsic value
ENTAEnanta Pharmaceuticals Inc.
$10.65+2.70%25
ABCLAbCellera Biologics Inc.
$12.28+0.82%10
XLOXilio Therapeutics, Inc.
$8.71+0.35%40
CYTKCytokinetics, Incorporated
$63.60+2.07%10
DERMJourney Medical Corp
$4.73+1.94%25
FBIOFortress Biotech Inc.
$1.97+1.55%59
RMTIRockwell Medical, Inc.
$8.05-0.49%37
BCYCBicycle Therapeutics PLC
$3.72+1.36%40

Spot a number that looks wrong? Check it in LITS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LITS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.